Prospective randomized pilot study of Y90 +/- sorafenib as bridge to transplantation in hepatocellular carcinoma

Journal of Hepatology

Volumn 61, Issue 2, 2014, Pages 309-317

  Kulik, Laura ^a   Vouche, Michael ^a   Koppe, Sean ^a   Lewandowski, Robert J ^a   Mulcahy, Mary F ^a   Ganger, Daniel ^a   Habib, Ali ^a   Karp, Jennifer ^a   Al Saden, Patrice ^a   Lacouture, Mario ^b   Cotliar, Jonathan ^a   Abecassis, Michael ^a   Baker, Talia ^a   Salem, Riad ^a  

^a NORTHWESTERN UNIVERSITY   (United States)

^b Division of Dermatology   (United States)

Author keywords

Hepatocellular carcinoma; Radioembolization; Sorafenib; Transplantation

Indexed keywords

SORAFENIB; YTTRIUM 90; ANTINEOPLASTIC AGENT; CARBANILAMIDE DERIVATIVE; NICOTINAMIDE; YTTRIUM;

ACUTE GRAFT REJECTION; ACUTE KIDNEY FAILURE; ADD ON THERAPY; ADULT; AGED; ARTICLE; ARTIFICIAL EMBOLISM; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG DOSE REDUCTION; DRUG SAFETY; ERYTHRODERMA; FEMALE; HEPATIC ENCEPHALOPATHY; HOSPITAL ADMISSION; HUMAN; LIVER CELL CARCINOMA; LIVER RESECTION; LIVER TRANSPLANTATION; LIVING DONOR; MALE; PILOT STUDY; PRIORITY JOURNAL; PROSPECTIVE STUDY; PSORIASIS; SURVIVAL RATE; ANALOGS AND DERIVATIVES; ARTIFICIAL EMBOLIZATION; CARCINOMA, HEPATOCELLULAR; GRAFT REJECTION; HEPATITIS C; LIVER NEOPLASMS; MIDDLE AGED; RADIATION DOSE; RANDOMIZED CONTROLLED TRIAL;

AGED; ANTINEOPLASTIC AGENTS; CARCINOMA, HEPATOCELLULAR; EMBOLIZATION, THERAPEUTIC; FEMALE; GRAFT REJECTION; HEPATITIS C; HUMANS; LIVER NEOPLASMS; LIVER TRANSPLANTATION; MALE; MIDDLE AGED; NIACINAMIDE; PHENYLUREA COMPOUNDS; PILOT PROJECTS; PROSPECTIVE STUDIES; RADIATION DOSAGE; YTTRIUM RADIOISOTOPES;

EID: 84904723995     PISSN: 01688278     EISSN: 16000641     Source Type: Journal    
DOI: 10.1016/j.jhep.2014.03.023     Document Type: Article

References (24)

1. H.B. El-Serag Hepatocellular carcinoma and hepatitis C in the United States Hepatology 36 2002 S74 S83
2. V. Mazzaferro, E. Regalia, R. Doci, S. Andreola, A. Pulvirenti, and F. Bozzetti et al. Liver transplantation for the treatment of small hepatocellular carcinomas in patients with cirrhosis N Engl J Med 334 1996 693 699
3. R. Salem, and R.J. Lewandowski Chemoembolization and radioembolization for hepatocellular carcinoma Clin Gastroenterol Hepatol 11 2013 604 611 [Quiz e643-604]
4. K. Sato, R.J. Lewandowski, J.T. Bui, R. Omary, R.D. Hunter, and L. Kulik et al. Treatment of unresectable primary and metastatic liver cancer with yttrium-90 microspheres (TheraSphere): assessment of hepatic arterial embolization Cardiovasc Intervent Radiol 29 2006 522 529
5. R. Salem, M. Gilbertsen, Z. Butt, K. Memon, M. Vouche, and R. Hickey et al. Increased quality of life among hepatocellular carcinoma patients treated with radioembolization, compared with chemoembolization Clin Gastroenterol Hepatol 11 2013 e1351
6. R. Salem, V. Mazzaferro, and B. Sangro Yttrium 90 radioembolization for the treatment of hepatocellular carcinoma: biological lessons, current challenges, and clinical perspectives Hepatology 58 2013 2188 2197
7. R. Salem, R.J. Lewandowski, M.F. Mulcahy, A. Riaz, R.K. Ryu, and S. Ibrahim et al. Radioembolization for hepatocellular carcinoma using Yttrium-90 microspheres: a comprehensive report of long-term outcomes Gastroenterology 138 2010 52 64
8. V. Mazzaferro, C. Sposito, S. Bhoori, R. Romito, C. Chiesa, and C. Morosi et al. Yttrium-90 radioembolization for intermediate-advanced hepatocellular carcinoma: a phase 2 study Hepatology 57 2013 1826 1837
9. M. Kudo, K. Imanaka, N. Chida, K. Nakachi, W.-Y. Tak, and T. Takayama et al. Phase III study of sorafenib after transarterial chemoembolisation in Japanese and Korean patients with unresectable hepatocellular carcinoma Eur J Cancer 47 2011 2117 2127
10. M. Vouche, L. Kulik, R. Atassi, K. Memon, R. Hickey, and D. Ganger et al. Radiological-pathological analysis of WHO, RECIST, EASL, mRECIST, and DWI: imaging analysis from a prospective randomized trial of Y90 +/- sorafenib Hepatology 58 2013 1655 1666
11. K.F. Schulz, D.G. Altman, D. Moher, and C. Group CONSORT 2010 statement: updated guidelines for reporting parallel group randomised trials Trials 11 2010 32
12. R. Salem, and K.G. Thurston Radioembolization with 90yttrium microspheres: a state-of-the-art brachytherapy treatment for primary and secondary liver malignancies: part 1: technical and methodologic considerations J Vasc Interv Radiol 17 2006 1251 1278
13. L. Liu, Y. Cao, C. Chen, X. Zhang, A. McNabola, and D. Wilkie et al. Sorafenib blocks the RAF/MEK/ERK pathway, inhibits tumor angiogenesis, and induces tumor cell apoptosis in hepatocellular carcinoma model PLC/PRF/5 Cancer Res 66 2006 11851 11858
14. R. Lencioni, and J.M. Llovet Modified RECIST (mRECIST) assessment for hepatocellular carcinoma Semin Liver Dis 30 2010 52 60
15. A.E. Truesdale, S.H. Caldwell, N.L. Shah, C.K. Argo, A.M. Al-Osaimi, and T.M. Schmitt et al. Sorafenib therapy for hepatocellular carcinoma prior to liver transplant is associated with increased complications after transplant Transpl Int 24 2011 991 998
16. J. Belghiti, B.I. Carr, P.D. Greig, R. Lencioni, and R.T. Poon Treatment before liver transplantation for HCC Ann Surg Oncol 15 2008 993 1000
17. A. Vitale, M.L. Volk, D. Pastorelli, S. Lonardi, F. Farinati, and P. Burra et al. Use of sorafenib in patients with hepatocellular carcinoma before liver transplantation: a cost-benefit analysis while awaiting data on sorafenib safety Hepatology 51 2010 165 173
18. T.A. Drixler, M.J. Vogten, E.D. Ritchie, T.J. van Vroonhoven, M.F. Gebbink, and E.E. Voest et al. Liver regeneration is an angiogenesis-associated phenomenon Ann Surg 236 2002 703 711 [Discussion 711-702]
19. A. Sergio, C. Cristofori, R. Cardin, G. Pivetta, R. Ragazzi, and A. Baldan et al. Transcatheter arterial chemoembolization (TACE) in hepatocellular carcinoma (HCC): the role of angiogenesis and invasiveness Am J Gastroenterol 103 2008 914 921
20. R.J. Lewandowski, L.M. Kulik, A. Riaz, S. Senthilnathan, M.F. Mulcahy, and R.K. Ryu et al. A comparative analysis of transarterial downstaging for hepatocellular carcinoma: chemoembolization vs. radioembolization Am J Transplant 9 2009 1920 1928
21. D. Sansonno, G. Lauletta, S. Russi, V. Conteduca, L. Sansonno, and F. Dammacco Transarterial chemoembolization plus sorafenib: a sequential therapeutic scheme for HCV-related intermediate-stage hepatocellular carcinoma: a randomized clinical trial Oncologist 17 2012 359 366
22. Lencioni R, Llovet JM, Han G, Tak W-Y, Yang J, Leberre M-A, et al. Sorafenib or placebo in combination with transarterial chemoembolization (TACE) with doxorubicin-eluting beads (DEBDOX) for intermediate-stage hepatocellular carcinoma (HCC). In: Phase II, randomized, double-blind SPACE trial. ASCO, Meeting Abstracts 2012;30:LBA154.
23. E. Gaudio, B. Barbaro, D. Alvaro, S. Glaser, H. Francis, and A. Franchitto et al. Administration of r-VEGF-A prevents hepatic artery ligation-induced bile duct damage in bile duct ligated rats Am J Physiol Gastrointest Liver Physiol 291 2006 G307 G317
24. Y. Matsumoto, G.W. McCaughan, D.M. Painter, and G.A. Bishop Evidence that portal tract microvascular destruction precedes bile duct loss in human liver allograft rejection Transplantation 56 1993 69 75